Isis Stock Hits New 52-Week High (ISIS)

NEW YORK ( TheStreet) -- Isis Pharmaceuticals (Nasdaq: ISIS) hit a new 52-week high Friday as it is currently trading at $29.21, above its previous 52-week high of $29.08 with 201,463 shares traded as of 10:10 a.m. ET. Average volume has been 1.7 million shares over the past 30 days.

Isis has a market cap of $3.23 billion and is part of the health care sector and drugs industry. Shares are up 172.7% year to date as of the close of trading on Wednesday.

Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Isis as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and compelling growth in net income. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and poor profit margins. You can view the full Isis Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..

null

More from Markets

Elon Musk, Carlos Ghosn, Huawei and Gilead Sciences - 5 Things You Must Know

Elon Musk, Carlos Ghosn, Huawei and Gilead Sciences - 5 Things You Must Know

Taking a Leap of Faith Is the Only Way to Invest Right Now

Taking a Leap of Faith Is the Only Way to Invest Right Now

What to Expect From the Markets in 2019 According to an Abbott Downing Executive

What to Expect From the Markets in 2019 According to an Abbott Downing Executive

Why Jim Cramer Isn't Surprised By the Jobs Report

Why Jim Cramer Isn't Surprised By the Jobs Report

Illinois Tool Works Stock Falls Despite In-Line Earnings Guidance

Illinois Tool Works Stock Falls Despite In-Line Earnings Guidance